Maxim Group restated their hold rating on shares of ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC) in a research report report published on Thursday morning.

Shares of ImmunoCellular Therapeutics (NASDAQ:IMUC) opened at 0.3095 on Thursday. The firm’s market cap is $4.90 million. ImmunoCellular Therapeutics has a 12-month low of $0.25 and a 12-month high of $6.32. The company’s 50 day moving average price is $0.51 and its 200-day moving average price is $1.63.

TRADEMARK VIOLATION WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.